« Return to News | Clinical Intelligence

Giant leap for HIV cure

Wednesday, January 11, 2012 11:09 AM

After 30 years of unsuccessful attempts, an HIV vaccine may be within reach. That’s what scientists at Crucell NV of the Netherlands (a subsidiary of Johnson & Johnson) are saying.

Crucell NV has successfully used a vaccine to protect monkeys from contracting its version of the HIV virus, SIV (simian immunodeficiency virus). After combining SIV proteins with different cold and pox viruses, scientists vaccinated monkeys, and then repeatedly exposed them to a genetically different SIV variation.

As few as 12% of monkeys exposed to the virus became infected after the first of six exposures, while monkeys treated with a placebo were infected 75% of the time. Although 12% may not sound like a lot, Crucell NV explained that SIV is nearly 100 times more infections than HIV.

A human trial is being planned by Harvard Medical School and U.S. Military HIV Research Program. The vaccine will be combined with a booster shot developed by the U.S. military and the National Institute of Allergy and Infectious Diseases.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.